港股频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 2月10日，信达生物(1801.HK)再度拉升涨超7%，现报92.5港元，总市值1568亿港元。消息上，信达生物日前与礼来制药达 成战略合作，推进肿瘤及免疫领域创新药全球研发。信达生物主导相关项目从药物发现至中国临床概念验证的研发工作， 礼来获大中华区外全球独家开发与商业化许可。信达生物将获88.5亿美元总付款，含3.5亿美元首付款及最高85亿美元里程 碑付款，还有权获大中华区外净销售额梯度销售分成。 摩根大通发表研究报告指出，信达生物与礼来达成战略合作，共同在全球范围开发聚焦于肿瘤和免疫学领域的新型生物制 剂。该行认为此次合作属正面惊喜，标志著信达生物迈向全球性生物制药公司历程中的又一个重要里程碑，并突显其研发 平台的实力。该行重申信达生物是其所覆盖的中国生物科技公司中的首选标的之一，予其"增持"评级，目标价为111港元。 ...

Group 1 - The core viewpoint of the article highlights the strategic collaboration between Innovent Biologics and Eli Lilly to jointly develop novel biologics focused on oncology and immunology globally [1] - The partnership is viewed as a positive surprise and marks a significant milestone in Innovent Biologics' journey towards becoming a global biopharmaceutical company, showcasing the strength of its R&D platform [1] - Innovent Biologics' management reiterated its long-term vision, primarily supported by a dual-engine growth strategy in the areas of generic biologics and oncology drugs [1] Group 2 - The report emphasizes the impressive execution capabilities of Innovent Biologics in its commercial and R&D product lines, as well as its strong business development abilities [1] - The firm maintains that Innovent Biologics is one of its top picks among Chinese biotech companies, reiterating an "overweight" rating with a target price of HKD 111 [1]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index (HSSCID) has surged by 4.32%, while the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) has increased by 3.50%, marking a three-day consecutive rise [1] - Innovent Biologics has entered into a global strategic collaboration with Eli Lilly to advance the development of new drugs in oncology and immunology, with a deal size exceeding expectations [1] - Under the agreement, Innovent will lead the research and development of related projects from drug discovery to clinical proof of concept in China, while Eli Lilly will obtain exclusive development and commercialization rights outside Greater China [1] Group 2 - According to Zhongyou Securities, although the innovative drug sector has experienced short-term fluctuations due to funding issues, the global participation trend has been fully reflected in 2025 [2] - Domestic new drugs are transitioning from early research to a phase of efficiency, indicating that the innovative drug sector is expected to enter a harvest period in the medium term [2] - The E Fund Hong Kong Stock Connect Innovative Drug ETF closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [2]

信达生物(1801.HK)再度拉升涨超7%，现报92.5港元，总市值1568亿港元。 ...

瑞银发表研报指，信达生物与礼来就多项早期肿瘤及免疫学资产达成合作。协议包括3.5亿美元的首付 款，潜在里程碑付款最高达85亿美元，以及基于净销售额的分层权利金。该行对两间公司进行第7次合 作持积极看法，并认为相较于以往的对外授权，是次成立新公司及共同开发模式，是一种新的合作模 式。信达生物指出，是次合作的潜在资产数量较同业其他类近的合作少，且财务条款优厚。更重要是， 该行注意到潜在资产包括信达生物研发管线中未出现过的新资产，为公司原先指引每年推进8至10个候 选药物进入临床阶段的目标带来上行空间。该行现予公司目标价137.4港元及"买入"评级。 ...

Summary of Innovent Biologics Conference Call Company Overview - **Company**: Innovent Biologics (1801.HK) - **Industry**: Biopharmaceuticals, focusing on oncology and immunology Key Points from the Conference Call Strategic Collaboration with Eli Lilly - Innovent announced a strategic collaboration with Eli Lilly on February 8, 2026, to advance early-stage oncology and immunology programs - The deal includes: - **Upfront Payment**: US$350 million - **Milestone Payments**: Up to US$8.5 billion - **Sales Royalties**: Tiered royalties from net sales outside of China - This collaboration marks the seventh agreement between Innovent and Eli Lilly, which began in 2015 with a three-mAb oncology deal [1][6] Roles and Responsibilities - Innovent will retain rights in China and lead the programs from concept to clinical proof of concept (POC) - Eli Lilly will manage late-stage global development and hold rights outside of China [1][2] Industry Trends - There is a growing trend of out-licensing deals from Chinese biopharma companies, indicating recognition from global partners of the potential in differentiated pipelines and fast POC delivery [1] Financial Outlook - Innovent is considered undervalued at current levels, with a market-implied weighted average cost of capital (WACC) of 12% reflecting only de-risked indications [1] - The company has a deep pipeline of over 30 assets, including commercialized products like sintilimab, a leading PD-1 inhibitor [1][6] Risks - Key risks identified include: - Intensifying competition in the PD-1/L1 market in China - Uncertain approval timelines for key candidates - Potential restrictions on off-label use due to safety issues - Failure of R&D projects [1][7] Financial Projections - **Market Capitalization**: HK$128.9 billion / US$16.5 billion - **Revenue Projections**: - 2024: Rmb 9,421.9 million - 2025: Rmb 12,783.0 million - 2026: Rmb 17,291.0 million - 2027: Rmb 20,681.3 million - **EBITDA Projections**: - 2024: (462.5) million - 2025: 1,274.8 million - 2026: 3,531.6 million - 2027: 5,106.1 million - **Price Target**: HK$102.85, representing a 29.4% upside from the current price of HK$79.50 [8] Conclusion - Innovent Biologics is positioned to maintain its leading role in the Chinese biotech sector, supported by a robust pipeline and strategic collaborations, particularly with Eli Lilly. The company faces significant risks but also presents a compelling investment opportunity given its growth potential and current valuation [1][8]

信达生物(1801.HK)再度拉升涨超7%，现报92.5港元，总市值1568亿港元。消息上，信达生物日前与礼来制药达成战略合作，推进肿瘤及免疫领域创新药全 球研发。信达生物主导相关项目从药物发现至中国临床概念验证的研发工作，礼来获大中华区外全球独家开发与商业化许可。信达生物将获88.5亿美元总付 款，含3.5亿美元首付款及最高85亿美元里程碑付款，还有权获大中华区外净销售额梯度销售分成。 摩根大通发表研究报告指出，信达生物与礼来达成战略合作，共同在全球范围开发聚焦于肿瘤和免疫学领域的新型生物制剂。该行认为此次合作属正面惊 喜，标志著信达生物迈向全球性生物制药公司历程中的又一个重要里程碑，并突显其研发平台的实力。该行重申信达生物是其所覆盖的中国生物科技公司中 的首选标的之一，予其"增持"评级，目标价为111港元。 ...

每经AI快讯，信达生物(01801.HK)涨超5%，截至发稿，涨5.56%，报90.1港元，成交额6.03亿港元。 ...

Core Viewpoint - The company, Innovent Biologics (01801), has seen its stock price increase by over 5%, currently trading at HKD 90.1, following the announcement of a strategic partnership with Eli Lilly to advance global R&D in oncology and immunology [1] Group 1: Strategic Partnership - Innovent Biologics has entered into its seventh strategic collaboration with Eli Lilly, focusing on innovative drug development in oncology and immunology [1] - The agreement includes an upfront payment of USD 350 million, with potential milestone payments totaling up to approximately USD 8.5 billion based on various development, regulatory, and commercialization milestones [1] - The partnership will also allow Innovent to receive a share of sales from related products in markets outside Greater China, enhancing its revenue potential [1] Group 2: Financial Implications - The upfront payment of USD 350 million is expected to be received soon, which will effectively cover the company's future overseas clinical investments [1] - Haitong International believes that the upfront and milestone payments will strengthen Innovent's financial safety net, while the sales share will provide long-term benefits from global market growth [1] - Goldman Sachs considers the current stock price undervalued, given the high implied weighted average cost of capital (12%), and has assigned a "Buy" rating with a target price of HKD 102.85 [1] Group 3: Competitive Positioning - The collaboration focuses on oncology and immunology, which aligns with Innovent's existing core pipeline, including IBI363 (PD1/IL2) and IBI343 (CLDN18.2ADC), enhancing overall competitiveness [1]

Core Viewpoint - The recent strategic partnership between Innovent Biologics and Eli Lilly is expected to enhance Innovent's financial stability and competitive position in the oncology and immunology sectors, with significant upfront and milestone payments involved [1][2]. Group 1: Financial Impact - Innovent Biologics has secured an upfront payment of $350 million from Eli Lilly, which will be received shortly and is intended to cover future overseas clinical investments [1]. - The total potential milestone payments could reach approximately $8.5 billion, providing a substantial financial cushion for the company [1]. - The sales sharing arrangement for products outside Greater China is expected to yield long-term benefits as the global market grows [2]. Group 2: Strategic Focus - The collaboration will focus on innovative drug development in oncology and immunology, aligning with Innovent's existing core pipeline, including IBI363 (PD1/IL2) and IBI343 (CLDN18.2 ADC) [2]. - This partnership is anticipated to enhance Innovent's overall competitiveness in the market by leveraging synergies with its current product offerings [2]. Group 3: Market Perception - Haitong International views the upfront and milestone payments as a reinforcement of Innovent's financial safety net, while Goldman Sachs believes the current stock price is undervalued, assigning a "Buy" rating with a target price of HKD 102.85 [2].